DK1803440T3 - Farmaceutisk formulering omfattende statinmikrokapsler i suspension af alkylestere af polyumættede fedtsyrer (PUFA) - Google Patents

Farmaceutisk formulering omfattende statinmikrokapsler i suspension af alkylestere af polyumættede fedtsyrer (PUFA)

Info

Publication number
DK1803440T3
DK1803440T3 DK05802903.4T DK05802903T DK1803440T3 DK 1803440 T3 DK1803440 T3 DK 1803440T3 DK 05802903 T DK05802903 T DK 05802903T DK 1803440 T3 DK1803440 T3 DK 1803440T3
Authority
DK
Denmark
Prior art keywords
pufa
fatty acids
alkyl esters
polyunsaturated fatty
suspension
Prior art date
Application number
DK05802903.4T
Other languages
English (en)
Inventor
Paolo Carminati
Antonio Parente
Original Assignee
Gp Pharm Sa
Defiante Farmaceutica Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gp Pharm Sa, Defiante Farmaceutica Sa filed Critical Gp Pharm Sa
Application granted granted Critical
Publication of DK1803440T3 publication Critical patent/DK1803440T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK05802903.4T 2004-10-19 2005-10-13 Farmaceutisk formulering omfattende statinmikrokapsler i suspension af alkylestere af polyumættede fedtsyrer (PUFA) DK1803440T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200402492A ES2255426B1 (es) 2004-10-19 2004-10-19 Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
PCT/ES2005/000542 WO2006045865A1 (es) 2004-10-19 2005-10-13 Formulación farmacéutica que comprende microcapsulas de estatinas suspendidas en ester alquílicos de ácidos grasos poliinsaturados (pufa)

Publications (1)

Publication Number Publication Date
DK1803440T3 true DK1803440T3 (da) 2010-10-04

Family

ID=36227494

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05802903.4T DK1803440T3 (da) 2004-10-19 2005-10-13 Farmaceutisk formulering omfattende statinmikrokapsler i suspension af alkylestere af polyumættede fedtsyrer (PUFA)

Country Status (22)

Country Link
US (1) US20090196920A1 (da)
EP (1) EP1803440B1 (da)
JP (1) JP4976302B2 (da)
KR (1) KR101413339B1 (da)
CN (2) CN101043873A (da)
AT (1) ATE469641T1 (da)
AU (1) AU2005298587B2 (da)
BR (1) BRPI0516152A (da)
CA (1) CA2583756C (da)
CY (1) CY1110751T1 (da)
DE (1) DE602005021668D1 (da)
DK (1) DK1803440T3 (da)
EA (1) EA012371B1 (da)
ES (2) ES2255426B1 (da)
IL (1) IL182466A (da)
MX (1) MX2007004655A (da)
NZ (1) NZ554265A (da)
PL (1) PL1803440T3 (da)
PT (1) PT1803440E (da)
SI (1) SI1803440T1 (da)
WO (1) WO2006045865A1 (da)
ZA (1) ZA200703509B (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2633268A1 (en) 2005-12-13 2007-06-21 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
JP2009534459A (ja) 2006-04-26 2009-09-24 ローズモント・フアーマシユーテイカルズ・リミテツド 液体経口組成物
EP2046305A2 (en) * 2006-06-26 2009-04-15 Valpharma S.A. Pharmaceutical composition for the oral administration of omega polyenoic fatty acids
CA2654529A1 (en) * 2006-07-06 2008-01-10 Teva Pharmaceutical Industries Ltd. Compositions with controlled pharmacokinetics
ITMI20072142A1 (it) 2007-11-08 2009-05-09 Yervant Zarmanian Composizioni farmaceutiche contenenti statine e derivati di acidi grassi omega-3
GB0724735D0 (en) 2007-12-19 2008-01-30 Psynova Neurotech Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
NZ600720A (en) * 2008-01-10 2012-12-21 Takeda Pharmaceutical A Seamless Capsule For A Liquid Pharmaceutical Composition
GB0818472D0 (en) * 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
ITFI20080243A1 (it) * 2008-12-15 2010-06-16 Valpharma Sa Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica.
EP3791880A1 (en) * 2009-04-29 2021-03-17 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa
ES2363964B1 (es) * 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
ES2364011B1 (es) * 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
ES2363965B1 (es) * 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
JP2013515719A (ja) * 2009-12-23 2013-05-09 デフィアンテ・ファルマセウティカ・ソシエダデ・アノニマ 循環器疾患の処置に有用な組み合わせ組成物
CA2706270C (en) * 2010-06-03 2020-01-07 Accucaps Industries Limited Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation
CA3065589C (en) 2010-06-03 2022-04-26 Catalent Ontario Limited Multi phase soft gel capsules, apparatus and method thereof
JP5829607B2 (ja) 2010-06-30 2015-12-09 持田製薬株式会社 ω３脂肪酸の配合製剤
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US20140127289A1 (en) 2010-11-29 2014-05-08 Armarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
KR101310710B1 (ko) * 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
WO2012170417A2 (en) 2011-06-06 2012-12-13 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
KR101466617B1 (ko) * 2011-11-17 2014-11-28 한미약품 주식회사 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
KR20150028233A (ko) 2012-05-07 2015-03-13 옴테라 파마슈티칼스, 인크. 스타틴 및 오메가-３ 지방산의 조성물
CN104602684B (zh) 2012-05-22 2016-08-17 健一制药株式会社 含有ω-3脂肪酸或其烷基酯和他汀类药物的口服给药的多层涂布形式的药物组合物
CN102824636A (zh) * 2012-08-15 2012-12-19 四川大学 一种含他汀类药物和多不饱和脂肪酸的药物组合物及其用途
WO2014182003A1 (en) * 2013-05-06 2014-11-13 Hanmi Pharm. Co., Ltd. Composite formulation comprising a film coating layer containing rosuvastatin or a pharmaceutically acceptable salt thereof
KR102240429B1 (ko) * 2013-05-06 2021-04-15 한미약품 주식회사 로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형
WO2015185240A1 (en) 2014-06-04 2015-12-10 Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. Compositions containing simvastatin in omega-3 polyunsaturated fatty acids
RU2614734C2 (ru) * 2015-05-21 2017-03-28 Татьяна Алексеевна Денисюк Способ получения нанокапсул розувастатина в каррагинане
KR101950907B1 (ko) 2016-02-05 2019-02-21 한국유나이티드제약 주식회사 지용성 약물 및 방유성 기제가 코팅된 고형제제를 포함하는 경구용 복합제제
WO2019143981A1 (en) * 2018-01-19 2019-07-25 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for delivering pharmaceutical agents
PT4056176T (pt) 2018-09-24 2024-05-27 Amarin Pharmaceuticals Ie Ltd Métodos de redução do risco de eventos cardiovasculares num indivíduo
WO2022129002A1 (en) * 2020-12-15 2022-06-23 Dsm Ip Assets B.V. Coarse dispersion comprising statin and vitamin e oil
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5312473B1 (da) 1971-05-24 1978-05-01
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5035896A (en) 1988-06-15 1991-07-30 Warner-Lambert Company Water insoluble drugs coated by coacervated fish gelatin
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
EP1165141A2 (en) 1999-03-31 2002-01-02 Abbott Laboratories Novel formulations comprising lipid-regulating agents
CA2365128A1 (en) 1999-03-31 2000-10-05 Abbott Laboratories Novel formulations comprising lipid-regulating agents
US6372251B2 (en) 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US6667064B2 (en) * 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
CA2427618A1 (en) * 2000-11-29 2002-06-06 Smithkline Beecham Corporation Composition containing statins and calcium for improved cardiovascular health
US20040235935A1 (en) * 2001-06-12 2004-11-25 Francis Vanderbist Oral pharmaceutical composition containing a statin derivative
WO2003013609A1 (en) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
JP4831965B2 (ja) * 2002-06-10 2011-12-07 エラン ファーマ インターナショナル，リミティド ＨＭＧ−ＣｏＡ還元酵素インヒビター誘導体（「スタチン」）を含むナノ粒子製剤、その新規組合せ、ならびにこれらの医薬組成物の製造
GB0217306D0 (en) * 2002-07-25 2002-09-04 Novartis Ag Compositions comprising organic compounds
NZ539624A (en) * 2002-09-27 2008-08-29 Martek Biosciences Corp Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
WO2004084870A1 (en) * 2003-03-28 2004-10-07 Sigmoid Biotechnologies Limited Solid oral dosage form containing seamless microcapsules

Also Published As

Publication number Publication date
ZA200703509B (en) 2008-09-25
JP2008517040A (ja) 2008-05-22
IL182466A0 (en) 2007-07-24
IL182466A (en) 2013-06-27
EA012371B1 (ru) 2009-10-30
CN102727462A (zh) 2012-10-17
ES2347055T3 (es) 2010-10-25
JP4976302B2 (ja) 2012-07-18
EA200700614A1 (ru) 2007-10-26
MX2007004655A (es) 2008-03-10
WO2006045865A1 (es) 2006-05-04
KR101413339B1 (ko) 2014-06-27
CA2583756C (en) 2013-12-24
NZ554265A (en) 2010-12-24
DE602005021668D1 (de) 2010-07-15
ATE469641T1 (de) 2010-06-15
EP1803440B1 (en) 2010-06-02
EP1803440A1 (en) 2007-07-04
BRPI0516152A (pt) 2008-08-26
ES2255426A1 (es) 2006-06-16
AU2005298587B2 (en) 2010-08-05
CA2583756A1 (en) 2006-05-04
PT1803440E (pt) 2010-08-31
ES2255426B1 (es) 2007-08-16
CN101043873A (zh) 2007-09-26
PL1803440T3 (pl) 2010-12-31
AU2005298587A1 (en) 2006-05-04
CY1110751T1 (el) 2015-06-10
SI1803440T1 (sl) 2010-10-29
KR20070083715A (ko) 2007-08-24
US20090196920A1 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
DK1803440T3 (da) Farmaceutisk formulering omfattende statinmikrokapsler i suspension af alkylestere af polyumættede fedtsyrer (PUFA)
UY29194A1 (es) Composiciones de aceites ricos en acidos grasos poliinsaturados (pufa)
IL180602A0 (en) Composition containing statins and omega-3 fatty acids
DK2436275T3 (da) Lipidsammensætning til forbedring af hjernefunktion
FR2903014B1 (fr) Composition cosmetique a base d'acide gras polyinsatures et ses utilisations
BRPI0705244A (pt) composição oleosa de ácido linolênico conjugado
AR042332A1 (es) Composiciones de gliceridos y metodos de elaboracion y uso de las mismas
ATE522264T1 (de) Extrahieren und entstearinieren von lipiden aus biomasse
ATE457720T2 (de) Weichgelatinekapsel mit mehrfach ungesättigten omega-3-fettsäuren
BRPI0418921A (pt) uso de ácidos graxos poliinsaturados, composição nutricional, e, uso de uma composição
DK1135996T3 (da) Anvendelse af syntetiske triglycerider på basis af konjugeret linolsyre som farvestabilisator i levnedsmidler
WO2008027991A3 (en) USE OF DPA(n-6) OILS IN INFANT FORMULA
BRPI0719182A2 (pt) Ácidos graxos omega 3 e agente dislipidêmico para redução de níveis de apo-b
NO20055784D0 (no) Fremstilling av polyumettede fettsyrer i oljesyrenk gjaer
ATE443515T1 (de) Omega-3-fettsäuren und omega-6-fettsäuren enthaltende zusammensetzung
EE200300297A (et) Eikosapentaeenhappe etüülestri ja dokosaheksaeenhappe etüülestri segu sisaldava essentsiaalse rasvhappe kasutamine
ATE422350T1 (de) Anisinsäure und glyceride enthaltende zusammensetzungen
BR0311764A (pt) Composição herbicida
NO20092131L (no) Fettsyrealkoholer
DE602004028454D1 (de) Mit metallionen ausgetauschte feststoffe zur verwevon fettsäuren und deren alkylestern
DE60101859D1 (de) Pinolensäure gegen Diabetes
ITMI20022511A1 (it) Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
AR053005A1 (es) Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa)
DE602006013755D1 (de) Fettlösliche Drogengestaltung
FR2894822B1 (fr) Composition pharmaceutique contenant des acides gras omega-3